A Randomized, Placebo-Controlled Study of the Continued Efficacy and Safety of SC Apomorphine in the Treatment of Off Episodes in Patients With "On/Off" or "Wearing-Off" Effects Associated With Late-Stage PD After Apomorphine Use

NCT00200525 Phase 3 COMPLETED

Study to measure the continued effectiveness of apomorphine after previous exposure of at least three months duration.

Details

Lead sponsor	Mylan Bertek Pharmaceuticals
Phase	Phase 3
Status	COMPLETED
Enrolment	60
Start date	2001-07
Completion	2002-06

Conditions

• Parkinson Disease

Interventions

• apomorphine HCl injection

Primary outcomes

• Change in UPDRS Motor Score 20 minutes after dosing of apomorphine or placebo